Cargando…

Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era

Introduction Bleomycin is a major antimitotic agent in the first-line treatment for Hodgkin's lymphoma. The main limitation of its use is its pulmonary toxicity. The objectives of this study are to find out the risk factors for the occurrence of bleomycin-induced lung toxicity in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Jennane, Selim, Ababou, Mounir, El Haddad, Mariyam, Ait Sahel, Omar, Mahtat, El Mehdi, El Maaroufi, Hicham, Doudouh, Abderrahim, Doghmi, Kamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994685/
https://www.ncbi.nlm.nih.gov/pubmed/35419251
http://dx.doi.org/10.7759/cureus.23993
_version_ 1784684158362058752
author Jennane, Selim
Ababou, Mounir
El Haddad, Mariyam
Ait Sahel, Omar
Mahtat, El Mehdi
El Maaroufi, Hicham
Doudouh, Abderrahim
Doghmi, Kamal
author_facet Jennane, Selim
Ababou, Mounir
El Haddad, Mariyam
Ait Sahel, Omar
Mahtat, El Mehdi
El Maaroufi, Hicham
Doudouh, Abderrahim
Doghmi, Kamal
author_sort Jennane, Selim
collection PubMed
description Introduction Bleomycin is a major antimitotic agent in the first-line treatment for Hodgkin's lymphoma. The main limitation of its use is its pulmonary toxicity. The objectives of this study are to find out the risk factors for the occurrence of bleomycin-induced lung toxicity in patients with Hodgkin's lymphoma and, on the other hand, to determine if positron emission tomography scan is a reliable means of early detection of this toxicity. Methods This is a retrospective study conducted in the clinical Hematology Department of Mohammed V Military Instruction Hospital, Rabat, Morocco. All patients with Hodgkin's lymphoma and treated with a bleomycin-based chemotherapy were included. The impact of different clinical and biological factors on the risk of bleomycin-induced lung toxicity occurrence was assessed using univariate and multivariate logistic regression. The benefit of positron emission tomography, usually performed as part of the re-assessment of Hodgkin’s lymphoma after two and four cycles, has been evaluated in the detection of bleomycin-induced lung toxicity. Results Among 124 patients included in the study, 18 (14.5%) patients experienced bleomycin-induced lung toxicity. On multivariate analysis, smoking (p = 0.038) and the use of the ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) compared to the escalated BEACOPPe regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) (p = 0.018) were statistically significant risk factors. After two and four courses of therapy, the positron emission tomography was able to predict the occurrence of bleomycin-induced lung toxicity before the appearance of clinical symptoms only in 36.4 % and 12.5% of patients, respectively. Conclusion Studies to identify risk factors for the development of bleomycin-induced lung toxicity are crucial to reduce toxicity in the treatment of Hodgkin's lymphoma. However, two- and four-cycle positron emission tomography scans cannot be considered as a reliable means of early detection of this toxicity.
format Online
Article
Text
id pubmed-8994685
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-89946852022-04-12 Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era Jennane, Selim Ababou, Mounir El Haddad, Mariyam Ait Sahel, Omar Mahtat, El Mehdi El Maaroufi, Hicham Doudouh, Abderrahim Doghmi, Kamal Cureus Oncology Introduction Bleomycin is a major antimitotic agent in the first-line treatment for Hodgkin's lymphoma. The main limitation of its use is its pulmonary toxicity. The objectives of this study are to find out the risk factors for the occurrence of bleomycin-induced lung toxicity in patients with Hodgkin's lymphoma and, on the other hand, to determine if positron emission tomography scan is a reliable means of early detection of this toxicity. Methods This is a retrospective study conducted in the clinical Hematology Department of Mohammed V Military Instruction Hospital, Rabat, Morocco. All patients with Hodgkin's lymphoma and treated with a bleomycin-based chemotherapy were included. The impact of different clinical and biological factors on the risk of bleomycin-induced lung toxicity occurrence was assessed using univariate and multivariate logistic regression. The benefit of positron emission tomography, usually performed as part of the re-assessment of Hodgkin’s lymphoma after two and four cycles, has been evaluated in the detection of bleomycin-induced lung toxicity. Results Among 124 patients included in the study, 18 (14.5%) patients experienced bleomycin-induced lung toxicity. On multivariate analysis, smoking (p = 0.038) and the use of the ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) compared to the escalated BEACOPPe regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) (p = 0.018) were statistically significant risk factors. After two and four courses of therapy, the positron emission tomography was able to predict the occurrence of bleomycin-induced lung toxicity before the appearance of clinical symptoms only in 36.4 % and 12.5% of patients, respectively. Conclusion Studies to identify risk factors for the development of bleomycin-induced lung toxicity are crucial to reduce toxicity in the treatment of Hodgkin's lymphoma. However, two- and four-cycle positron emission tomography scans cannot be considered as a reliable means of early detection of this toxicity. Cureus 2022-04-09 /pmc/articles/PMC8994685/ /pubmed/35419251 http://dx.doi.org/10.7759/cureus.23993 Text en Copyright © 2022, Jennane et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Jennane, Selim
Ababou, Mounir
El Haddad, Mariyam
Ait Sahel, Omar
Mahtat, El Mehdi
El Maaroufi, Hicham
Doudouh, Abderrahim
Doghmi, Kamal
Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
title Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
title_full Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
title_fullStr Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
title_full_unstemmed Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
title_short Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
title_sort bleomycin-induced lung toxicity in hodgkin's lymphoma: risk factors in the positron emission tomography era
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994685/
https://www.ncbi.nlm.nih.gov/pubmed/35419251
http://dx.doi.org/10.7759/cureus.23993
work_keys_str_mv AT jennaneselim bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera
AT ababoumounir bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera
AT elhaddadmariyam bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera
AT aitsahelomar bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera
AT mahtatelmehdi bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera
AT elmaaroufihicham bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera
AT doudouhabderrahim bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera
AT doghmikamal bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera